title: Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.
abstract: OBJECTIVE
  Head-to-head optical coherence tomography (OCT) data comparing metallic stents with bioresorbable vascular scaffolds (BVS) are lacking. This study assessed vascular healing at 9-month follow-up after implantation of everolimus- and biolimus-eluting stents (EES; BES) and everolimus-eluting BVS.
  
  
  METHODS
  OCT was performed in 74 patients enrolled in the EVERBIO II (NCT01711931) trial (23 with EES: 26 lesions, 7 625 struts; 23 with BES: 26 lesions, 6 140 struts; 28 with BVS: 33 lesions, 10 891 struts). OCT images were acquired using the pullback and nonocclusive flushing technique and analysed offline.
  
  
  RESULTS
  BVS demonstrated fewer uncovered struts per patient (12 ± 27 [3.8 ± 8.4%] vs 59 ± 55 [21.8 ± 13.7%] in the EES&BES group, p <0.001), and thicker neointimal hyperplasia (BVS 102 ± 44 µm vs EES&BES 66 ± 36 µm, p <0.01). There was no significant difference with regard to malapposed struts (2.1 ± 2.7% in the BVS vs 4.4 ± 8.8% in the EES&BES group, p = 0.41). In a predefined signal intensity scale, quantitative analysis of the "key component" (black) revealed lower intensity in BVS than EES&BES (14 ± 23% vs 13 ± 12%, p = 0.007). Intensity was lower in polylactide-containing stents (BVS&BES) than in EES (15 ± 19% vs 10 ± 10%, p <0.001).
  
  
  CONCLUSIONS
  BVS has fewer uncovered struts and presents with a thicker neointimal coverage compared with EES&BES. It is not known whether this improved capping correlates with superior vascular healing. Polylactide-containing stents (BVS and BES) demonstrate lower peristrut intensity compared with EES.
authors.affiliation: Hospital and University Fribourg, Fribourg, Switzerland.
authors.forename: Zacharenia
authors.initials: Z
authors.lastname: Kallinikou
authors.affiliation: Hospital and University Fribourg, Fribourg, Switzerland.
authors.forename: Diego
authors.initials: D
authors.lastname: Arroyo
authors.affiliation: Hospital and University Fribourg, Fribourg, Switzerland.
authors.forename: Mario
authors.initials: M
authors.lastname: Togni
authors.affiliation: Hospital and University Fribourg, Fribourg, Switzerland.
authors.forename: Sonja
authors.initials: S
authors.lastname: Lehman
authors.affiliation: Hospital and University Fribourg, Fribourg, Switzerland.
authors.forename: Noé
authors.initials: N
authors.lastname: Corpataux
authors.affiliation: Hospital and University Fribourg, Fribourg, Switzerland.
authors.forename: Malica
authors.initials: M
authors.lastname: Cook
authors.affiliation: Hospital and University Fribourg, Fribourg, Switzerland.
authors.forename: Olivier
authors.initials: O
authors.lastname: Müller
authors.affiliation: Hospital and University Fribourg, Fribourg, Switzerland.
authors.forename: Gérard
authors.initials: G
authors.lastname: Baeriswyl
authors.affiliation: Hospital and University Fribourg, Fribourg, Switzerland.
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Stauffer
authors.affiliation: Hospital and University Fribourg, Fribourg, Switzerland.
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Goy
authors.affiliation: Hospital and University Fribourg, Fribourg, Switzerland.
authors.forename: Serban-George
authors.initials: SG
authors.lastname: Puricel
authors.affiliation: Hospital and University Fribourg, Fribourg, Switzerland.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Cook
mesh_terms: D020341:Absorbable Implants; D000368:Aged; D003324:Coronary Artery Disease / Q000473:pathology / Q000628:therapy*; D023903:Coronary Restenosis; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D016037:Single-Blind Method; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D054457:Tissue Scaffolds; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; C518022:umirolimus; D020123:Sirolimus